KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Esperion Therapeutics (ESPR) FCF Margin (2019 - 2025)

Esperion Therapeutics' FCF Margin history spans 7 years, with the latest figure at 26.86% for Q4 2025.

  • For Q4 2025, FCF Margin rose 7743.0% year-over-year to 26.86%; the TTM value through Dec 2025 reached 3.25%, up 397.0%, while the annual FY2025 figure was 3.25%, 397.0% up from the prior year.
  • FCF Margin reached 26.86% in Q4 2025 per ESPR's latest filing, up from 4.91% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 39.03% in Q1 2024 to a low of 1116.42% in Q1 2021.
  • Average FCF Margin over 5 years is 182.39%, with a median of 105.44% recorded in 2023.
  • The largest YoY upside for FCF Margin was 267461bps in 2021 against a maximum downside of -18323bps in 2021.
  • A 5-year view of FCF Margin shows it stood at 374.69% in 2021, then soared by 40bps to 225.7% in 2022, then soared by 49bps to 114.9% in 2023, then soared by 56bps to 50.57% in 2024, then surged by 153bps to 26.86% in 2025.
  • Per Business Quant, the three most recent readings for ESPR's FCF Margin are 26.86% (Q4 2025), 4.91% (Q3 2025), and 38.14% (Q2 2025).